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Source of ﬁnancjournal homepage: www.elsevier .com/ locate / jva lResponse to Letter to the Editor
Cost-Effectiveness of Expanded Newborn Screening in Texas—AuthorWe thank Professor Chie and colleagues for their letter regarding the
article entitled “Cost-effectiveness of Expanded Newborn Screening
in Texas” published in the July 2012 issue of Value in Health.
We have conducted a thorough review of the article and the
analysis presented in Table 6. We agree that because of a
calculation error, erroneous incremental cost-effectiveness ratio
values were reported.
We apologize for the errors and conﬁrm that despite these
errors, the overall ﬁndings of the cost-effectiveness analysis
remain unchanged. The corrected results are still robust and
can be cost-effective at the commonly accepted willingness-to-
pay threshold of $50,000/quality-adjusted life-year.
Corrections: “Cost-effectiveness of Expanded Newborn
Screening in Texas” by Tiwana, Rascati, and Park Value Health
2012;15:613–21
Paragraph 1 under Results (page 616) should now read as
follows:
Table 6 shows the lifetime estimates of cost and effectiveness
(with and without screening) for each expanded disorder cate-
gory. For HCY, screening was the dominant strategy compared
with not screening. For ASA and CIT, screening resulted in ane cost and effectiveness by disorder” shou
With screening
Cost ($) Effectiveness
681,455.00 14.34
267,699.00 24.09
136,607.00 25.03
266,711.00 24.56
291,269.00 24.73
184,436.00 23.46
ial support: The author has no other ﬁnancial relaestimated ICER of about $47,000 per QALY, which is higher than
that for other disorders included in the analysis. For all the other
disorder categories, screening resulted in an ICER of approxi-
mately $15,000 or less per QALY.
The ﬁrst sentence of paragraph 2 under Discussion (page 618)
should now read as follows:
For ASA and CIT, screening costs an estimated additional
$47,000 per QALY at the base rate of 3%, which is likely due to the
higher cost of treatment for these disorders.Simrandeep K. Tiwana, MBA, PhD
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Without screening
Cost ($) Effectiveness ICER ($/QALY)
538,334.00 11.3 47,079.28
333,594.00 21.04 Dominant
36,303.00 5.94 5,254.27
250,678.00 19.84 3,396.82
217,145.00 19.91 15,378.42
142,468.00 15.02 4,972.51tionships to disclose.
